Video

Rapid Readouts: Final Analysis Results From the Phase 3 TITAN Study

Author(s):

Kim N. Chi, MD, BC Cancer

Kim N. Chi, MD, presents slides from the 2021 ASCO Genitourinary Cancers Symposium for the final results from the phase 3 TITAN study of apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy.

Related Videos
RLY-2608
BOVen
RMC-6236
LTE-1 ASPEN LTFU
Data from an Ongoing Phase 1/1b Study BGB-11417-101
Chandler Park, MD, FACP, genitourinary medical oncologist, Norton Cancer Institute
Preliminary Results from the IMMagine-1 Trial
SNDX-5613
Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
Related Content
Jeff Patton, MD
January 22nd 2025

Second Cycle of Medicare Drug Price Negotiations Includes 4 Oncologic Agents

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Prostate Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
January 20th 2025

Development of LAVA-1207 Discontinues in mCRPC

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Leuprolide Mesylate in Advanced Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
January 13th 2025

PDUFA Date Set for 3-Month Variation of Leuprolide Mesylate in Advanced Prostate Cancer

Prostate Cancer
December 11th 2024

CAN-2409 Improves DFS in Intermediate/High-Risk Localized Prostate Cancer